Searched for
DRUG MAKER CIPLA
India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Cipla to fully acquire Inzpera HealthscienceDrug maker Cipla has acquired Inzpera Healthscience for approximately Rs 111 crore. This strategic move combines Inzpera's paediatric produ...
- Cipla recovers after falling 5% on fears of action against Goa unitObservations are largely related to procedure and SOP lapses, Equirius said.
- Cipla's U-turn: Happily ever after?In a foes-turn-friends move announced on February 27, the Mumbai-based drug maker announced that it will partner Swiss biotech company Roch...
- Roche and Cipla tie up to market anti cancer drugsRoche said this partnership will also enable it to focus on bringing new, transformative medicines to patients in India.
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- Delhi High Court quashes Cipla's appeal, says it can't market generics of Novartis' OnbrezThe court said it can't make a definitive conclusion that Novartis' imports of Onbrez were insufficient to meet the demands COPD patients f...
- Delhi High Court upholds ruling barring Cipla from selling copies of Novartis drugAccording to the judgment, Cipla had claimed that 10 tablets of Onbrez cost Rs 677 as opposed to its own drug priced at Rs 130.
- Cipla’s inhalable insulin fails to get approval for trials on Indian patientsCipla had based its application to the panel on the bioequivalence studies with Exubra, an inhalation drug and device combination that was ...
- Cipla divests 16.7 per cent stake in Chase Pharma to AllerganChase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla...
- Cipla aims to reach $1bn India sales through tie-upsCipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...
- Drug overcharging case: Supreme Court directs Cipla to pay Rs 175.07 croreThe authority has charged Cipla of charging higher prices for a set of drugs than the ceiling price based on a fixed formula.
- Cipla seals Invagen and Exelan deals in USThe deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...
- Cipla looks to acquire 25% stake in South African coCipla said it could take a decision to buy stake of up to 25 per cent in South Africa-based, Cipla Medpro in next board meeting. Cipla Medp...
- Cipla to invest about Rs 300 cr to acquire stakes in 2 cosDrug maker Cipla on Tuesday said it will invest USD 65 million (nearly Rs 300 crore) over the next three years with a Chinese joint venture...
- Cipla scores a generic win over RocheThe Delhi HC rejected an injunction plea by Swiss drug major Roche to prevent Cipla from manufacturing generic versions of anti-cancer drug...
Load More
